Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib

Imatinib is a long‐term, oral, targeted therapy for high‐risk resected and advanced gastrointestinal stromal tumours (GIST). It is known that sarcopenia affects prognosis and treatment tolerance in patients with various solid cancers. We analysed lumbar skeletal muscle index changes in imatinib‐treated GIST patients. Imatinib tolerance was also assessed to evaluate the influence of pre‐treatment sarcopenia.

• Publication year

  2015

• Venue

  Journal of Cachexia, Sarcopenia and Muscle

• Publication date

  2015-06-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcsm.12047PMID 26673372PMCID 4670743
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib

  2017cited by this paper
• Sarcopenia: describing rather than defining a condition

  2014cited by this paper
• Sarcopenia Is Linked to Treatment Toxicity in Patients With Metastatic Colorectal Cancer

  2014cited by this paper
• Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer

  2014cited by this paper
• Low skeletal muscle is associated with toxicity in patients included in phase I trials

  2014cited by this paper
• Are we closer to having drugs to treat muscle wasting disease?

  2014cited by this paper
• Sarcopenia in patients with bladder cancer undergoing radical cystectomy: Impact on cancer‐specific and all‐cause mortality

  2014cited by this paper
• Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients

  2013cited by this paper
• Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer

  2013cited by this paper
• Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

  2013influential reference
• Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma

  2012cited by this paper
• Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study.

  2012cited by this paper
• Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery

  2012cited by this paper
• Cancer cachexia: impact, mechanisms and emerging treatments

  2012cited by this paper
• Imatinib treatment inhibit IL‐6, IL‐8, NF‐KB and AP‐1 production and modulate intracellular calcium in CML patients

  2012cited by this paper
• A pilot study of temsirolimus and body composition

  2012cited by this paper
• Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

  2012cited by this paper
• Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia

  2012cited by this paper
• Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis

  2012cited by this paper
• Definition and classification of cancer cachexia: an international consensus.

  2011influential reference
• Sarcopenia: European consensus on definition and diagnosis

  2010cited by this paper
• Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.

  2010cited by this paper
• Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.

  2010cited by this paper
• An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity

  2010cited by this paper
• Inflammatory burden and amino acid metabolism in cancer cachexia

  2009cited by this paper
• Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

  2009cited by this paper
• Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.

  2008cited by this paper
• A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care.

  2008cited by this paper
• Cachexia: a new definition.

  2008cited by this paper
• Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

  2008cited by this paper
• Cancer Cachexia Signaling Pathways Continue to Emerge Yet Much Still Points to the Proteasome

  2007cited by this paper
• Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity

  2007cited by this paper
• Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image.

  2004cited by this paper
• Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

  2004cited by this paper
• CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

  2003cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002influential reference
• Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography.

  1998cited by this paper
• Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

  1980cited by this paper
• Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People . Sarcopenia: European consensus on definition and diagnosis: Report the European Working Group on Sarcopenia in Older People.

  year unknowncited by this paper

• The Prognostic Value of Body Composition Analysis on Non-Enhanced CT for Risk Stratification in Gastrointestinal Stromal Tumors: A Retrospective Study

  2025cites this paper
• Linking the Planetary Health Diet Index to sarcopenia: the mediating effect of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR)

  2025cites this paper
• The correlation of sarcopenia and adverse events of imatinib therapy postoperatively in gastrointestinal stromal tumor through computed tomography quantitative body composition.

  2024cites this paper
• CT-based assessment of sarcopenia for differentiating wild-type from mutant-type gastrointestinal stromal tumor

  2023cites this paper
• Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib

  2023influential citation
• Gastric Cancer with Sarcopenia: an Area Worth Focusing On

  2023cites this paper
• Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST

  2022cites this paper
• Serum creatinine/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours

  2022cites this paper
• Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate

  2022cites this paper
• Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors

  2022influential citation
• Association between preoperative skeletal muscle mass depletion and poor relapse-free survival in patients with gastrointestinal stromal tumors after complete resection.

  2022cites this paper
• Sarcopenia as a novel prognostic factor in the patients of primary localized gastrointestinal stromal tumor

  2022cites this paper
• Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles

  2022cites this paper
• A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters

  2021cites this paper
• Nutritional and anticancer therapy in cancer patients with low muscle mass

  2021cites this paper
• The Impact of Preoperative Sarcopenia on Survival Prognosis in Patients Receiving Neoadjuvant Therapy for Esophageal Cancer: A Systematic Review and Meta-Analysis

  2021cites this paper
• Nutritional and anticancer therapy in cancer patients with low muscle mass

  2021cites this paper
• Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis

  2020cites this paper
• Chemotherapy-Induced Sarcopenia

  2020cites this paper
• BODY COMPOSITION IMPACT ON SURVIVAL AND TOXICITY OF TREATMENT IN PANCREATIC CANCER: CROSS-SECTIONAL PILOT STUDY.

  2020cites this paper
• Cancer-Associated Muscle Wasting—Candidate Mechanisms and Molecular Pathways

  2020cites this paper
• Sarcopenia as a novel prognostic factor in the patients of primary localized gastrointestinal stromal tumor

  2020cites this paper
• Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy

  2019cites this paper
• Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival.

  2019cites this paper
• Current technologies in body composition assessment: advantages and disadvantages.

  2019cites this paper
• Sarcopenia associated with chemotherapy and targeted agents for cancer therapy.

  2019cites this paper
• Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments

  2018cites this paper
• Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018

  2018cites this paper
• Do we need a reference standard for the muscle mass measurements?

  2018cites this paper
• Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes

  2018cites this paper
• A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes

  2018cites this paper
• Radiologically Determined Sarcopenia Predicts Morbidity and Mortality Following Abdominal Surgery: A Systematic Review and Meta-Analysis

  2017cites this paper
• Casting the net broader to confirm our imaginations: the long road to treating wasting disorders

  2017cites this paper
• A comparison of research into cachexia, wasting and related skeletal muscle syndromes in three chronic disease areas.

  2017cites this paper
• An analysis of the types of recently published research in the field of cachexia

  2017cites this paper
• The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma.

  2017cites this paper
• Surgical Management in Patients with Gastrointestinal Stromal Tumors: A Single-Center Experience

  2016cites this paper
• Conference on ‘ Nutrition at key life stages : new fi ndings , new approaches ’ Symposium 4 : Clinical nutrition : gold standards and practical demonstrations Sarcopenia and cachexia in the era of obesity : clinical and nutritional impact

  2016cites this paper
• Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later

  2016cites this paper
• Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact

  2016cites this paper
• Conference on ‘ Nutrition at key life stages: new fi ndings, new approaches ’

  year unknowncites this paper